Abstract
The generation of patient-specific stem cells by reprogramming somatic cells to induced pluripotent stem cells (iPSC) provides the basis for a promising new type of in vitro disease models. Patient-specific iPSC derived from individuals with hereditary disorders can be differentiated into somatic cells in vitro, thus allowing the pathophysiology of the diseases to be studied on a cellular level. Different types of long-QT syndrome have been successfully modeled using this approach, demonstrating that the iPSC-derived patient-specific cardiomyocytes recapitulated key features of the disease in vitro. This approach will likely serve to model other monogenetic or polygenetic cardiovascular disorders in the future. Moreover, test platforms based on patient-specific iPSC could be used to test the potential of drug candidates to induce QT-interval prolongation or other unwanted side effects, screen for novel cardiovascular drugs, or to tailor medical therapy to the specific needs of a single patient.
Similar content being viewed by others
References
Antzelevitch C (2005) Role of transmural dispersion of repolarization in the genesis of drug-induced torsades de pointes. Heart Rhythm 2(Suppl 2):S9–S15
Antzelevitch C, Brugada P, Borggrefe M, Brugada J, Brugada R, Corrado D et al (2005) Brugada syndrome: report of the second consensus conference: endorsed by the heart rhythm society and the European heart rhythm association. Circulation 111(5):659
Azaouagh A, Churzidse S, Konorza T, Erbel R (2011) Arrhythmogenic right ventricular cardiomyopathy/dysplasia: a review and update. Clin Res Cardiol 100:383–394
Beffagna G, Occhi G, Nava A, Vitiello L, Ditadi A, Basso C et al (2005) Regulatory mutations in transforming growth factor-beta3 gene cause arrhythmogenic right ventricular cardiomyopathy type 1. Cardiovasc Res 65:366–373
Brown ME, Rondon E, Rajesh D, Mack A, Lewis R, Feng X et al (2010) Derivation of induced pluripotent stem cells from human peripheral blood T lymphocytes. PLoS One 5(6):e11373
Dessertenne F (1966) La tachycardie ventriculaire à deux foyers opposés variables. Arch Mal Coeur 59:263–272
Ebert AD, Yu J, Rose FF Jr, Mattis VB, Lorson CL, Thomson JA et al (2009) Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 457:277–280
Eckardt L, Haverkamp W, Borggrefe M, Breithardt G (1998) Experimental models of torsade de pointes. Cardiovasc Res 39:178–193
Fatima A, Xu G, Shao K, Papadopoulos S, Lehmann M, Arnáiz-Cot JJ et al (2011) Cell Physiol Biochem 28:592–597
Gaita F, Giustetto C, Bianchi F, Wolpert C, Schimpf R, Riccardi R et al (2003) Short QT syndrome: a familial cause of sudden death. Circulation 108(8):965–970
Giorgi MA, Bolanos R, Gonzalez CD, Di Girolamo G (2010) QT interval prolongation: preclinical and clinical testing arrhythmogenesis in drugs and regulatory implications. Curr Drug Saf 5:54–57
Giustetto C, Di Monte F, Wolpert C, Borggrefe M, Schimpf R, Sbragia P et al (2006) Short QT syndrome: clinical findings and diagnostic-therapeutic implications. Eur Heart 27(20):2440
He J-Q, Ma Y, Lee Y, Thomson JA, Kamp TJ (2003) Human embryonic stem cells develop into multiple types of cardiac myocytes. Action potential characterization. Circ Res 93:32–39
Itzhaki I, Maizels L, Huber I, Zwi-Dantsis L, Caspi O, Winterstern A et al (2011) Modelling the long-QT syndrome with induced pluripotent stem cells. Nature 471(7337):225–229
Jung CB, Moretti A, Mederos Y Schnitzler M, Iop L, Storch U et al (2011) Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia. EMBO Mol Med. doi:10.1002/emmm.201100194
Kannankeril PJ, Roden DM, Norris KJ, Whalen SP, George AL Jr, Murray KT (2005) Genetic susceptibility to acquired long QT syndrome: pharmacologic challenge in first-degree relatives. Heart Rhythm 2(2):134–140
Keller GM (1995) In vitro differentiation of embryonic stem cells. Curr Opin Cell Biol 7(6):862–869
Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH (2002) Timing of new black box warnings and withdrawals for prescription medications. JAMA 287:2215–2220
Lee G, Papapetrou EP, Kim H, Chambers SM, Tomishima MJ, Fasano CA et al (2009) Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature 461:402–406
Lehnart SE, Ackerman MJ, Benson W, Brugada R, Clancy CE, Donahue JK et al (2007) Inherited arrhythmias. A national heart, lung, and blood institute and office of rare diseases workshop consensus report about the diagnosis, phenotyping, molecular mechanisms, and therapeutic approaches for primary cardiomyopathies of gene mutations affecting ion channel function. Circulation 116:2325–2345
Maltsev VA, Rohwedel J, Hescheler J, Wobus AM (1993) Embryonic stem cells differentiate in vitro into cardiomyocytes representing sinusnodal, atrial and ventricular cell types. Mech Dev 44(1):41–50
Maron BJ, Thompson PD, Puffer JC, McGrew CA, Strong WB, Douglas PS et al (1996) Cardiovascular preparticipation screening of competitive athletes. A statement for health professionals from the sudden death committee (clinical cardiology) and congenital cardiac defects committee (cardiovascular disease in the young), American heart association. Circulation 94:850–856
Matsa E, Rajamohan D, Dick E, Young L, Mellor I, Stainforth A et al (2011) Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long-QT syndrome type 2 mutation. Eur Heart J 32(8):952–962
Merner ND, Hodgkinson KA, Haywood AF, Connors S, French VM, Drenckhahn JD et al (2008) Arrhythmogenic right ventricular cardiomyopathy type 5 is a fully penetrant, lethal arrhythmic disorder caused by a missense mutation in the TMEM43 gene. Am J Hum Genet 82:809–821
Moretti A, Bellin M, Welling A, Jung CB, Lam JT, Bott-Flügel L et al (2010) Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med 363(15):1397–1409
Novak A, Shtrichman R, Germanguz I, Segev H, Zeevi-Levin N, Fishman B et al (2010) Enhanced reprogramming and cardiac differentiation of human keratinocytes derived from plucked hair follicles using a single excisable lentivirus. Cell Reprogram 12(6):665–678
Novak A, Barad L, Zeevi-Levin N, Shick R, Shtreichman R, Lorber A et al (2011) Cardiomyocytes generated from CPVT(D307H) patients are arrhythmogenic in response to β-adrenergic stimulation. J Cell Mol Med 16(3):468–482
Okita K, Ichisaka T, Yamanaka S (2007) Generation of germline-competent induced pluripotent stem cells. Nature 448(7151):313–317
Peal DS, Mills RW, Lynch SN, Mosley JM, Lim E, Ellinor PT et al (2011) Novel chemical suppressors of long QT syndrome identified by an in vivo functional screen. Circulation 123:23–30
Priori S, Chen SRW (2011) Inherited dysfunction of sarcoplasmic reticulum Ca2+ handling and arrhythmogenesis. Circ Res 108:871–883
Richard P, Charron P, Carrier L, Ledeuil C, Cheav T, Pichereau C et al (2003) Hypertrophic cardiomyopathy. Distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation 107:2227–2232
Sanguinetti MC, Jiang C, Curran ME, Keating MT (1995) A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 81:299–307
Schmitt N, Calloe K, Nielsen NH, Buschmann M, Speckmann EJ, Schulze-Bahr E et al (2007) The novel C-terminal KCNQ1 mutation M520R alters protein trafficking. Biochem Biophys Res Commun 358(1):304–310
Schwartz PJ, Stramba-Badiale M, Crotti L, Pedrazzini M, Besana A, Bosi G et al (2009) Prevalence of the congenital long-QT syndrome. Circulation 120:1761–1767
Sidhu KS (2011) New approaches for the generation of induced pluripotent stem cells. Expert Opin Biol Ther 11(5):569–579
Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126(4):663–676
Takahashi T, Lord B, Schulze PC, Fryer RM, Sarang SS, Gullans SR et al (2003) Ascorbic acid enhances differentiation of embryonic stem cells into cardiac myocytes. Circulation 107:1912–1916
Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K et al (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131(5):861–872
Thomas D, Khali M, Alter M, Schweizer PA, Karle CA, Wimmer AB et al (2010) Biophysical characterization of KCNQ1 P320 mutations linked to long QT syndrome 1. J Mol Cell Cardiol 48(1):230–237
Tiburcy M, Didié M, Boy O, Christalla P, Doeker S, Naito H, Karikkineth BC et al (2011) Terminal differentiation, advanced organotypic maturation, and modeling of hypertrophic growth in engineered heart tissue. Circ Res 109(10):1105–1114
Tiso N, Stephan DA, Nava A, Bagattin A, Devaney JM, Stanchi F et al (2001) Identification of mutations in the cardiac ryanodine receptor gene in families affected with arrhythmogenic right ventricular cardiomyopathy type 2 (ARVD2). Hum Mol Genet 10:189–194
Tran TH, Wang X, Browne C, Zang Y, Schinke M, Izumo S et al (2009) Wnt3a-induced mesoderm formation and cardiomyogenesis in human embryonic stem cells. Stem Cells 27:1869–1878
Tulloch NL, Muskheli V, Razumova MV, Korte FS, Regnier M, Hauch KD et al (2011) Growth of engineered human myocardium with mechanical loading and vascular coculture. Circ Res 109(1):47–59
van Tintelen JP, Entius MM, Bhuiyan ZA, Jongbloed R, Wiesfeld ACP, Wilde AAM et al (2006) Plakophilin-2 mutations are the major determinant of familial arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circulation 113:1650–1658
Watkins H, Ashrafian H, Redwood C (2011) Inherited cardiomyopathies. N Engl J Med 364:1643–1656
Wilde AA, Antzelevitch C, Borggrefe M, Brugada J, Brugada R, Brugada P et al (2002) Proposed diagnostic criteria for the Brugada syndrome. Eur Heart J 23(21):1648
Wu G, Ai T, Kim JJ, Mohapatra B, Xi Y, Li Z et al (2008) α-1-syntrophin mutation and the long-QT syndrome: a disease of sodium channel disruption. Circ Arrhythm Electrophysiol 1(3):193–201
Yang P, Kanki H, Drolet B, Yang T, Wei J, Viswanathan PC et al (2002) Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation 105(16):1943–1948
Yang Y, Yang Y, Liang B, Liu J, Li J, Grunnet M et al (2010) Identification of a Kir3.4 mutation in congenital long QT syndrome. Am J Hum Genet 86:872–880
Yazawa M, Hsue B, Jia X, Pasca A, Bernstein JA, Hallmayer J et al (2011) Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. Nature 471(7337):230–234
Ye L, Chang JC, Lin C, Sun X, Yu J, Kan YW (2009) Induced pluripotent stem cells offer new approach to therapy in thalassemia and sickle cell anemia and option in prenatal diagnosis in genetic diseases. Proc Natl Acad Sci USA 106(24):9826–9830
Yu J, Vodyanìk MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S et al (2007) Induced pluripotent stem cell lines derived from human somatic cells. Science 318(5858):1917–1920
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dirschinger, R.J., Goedel, A., Moretti, A. et al. Recapitulating Long-QT Syndrome Using Induced Pluripotent Stem Cell Technology. Pediatr Cardiol 33, 950–958 (2012). https://doi.org/10.1007/s00246-012-0286-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00246-012-0286-8